Russell Investments Group’s Esperion Therapeutics ESPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $377K | Buy |
119,340
+97,857
| +456% | +$274K | ﹤0.01% | 2912 |
|
|
2026
Q1 | $58.9K | Sell |
21,483
-90
| -0.4% | -$285 | ﹤0.01% | 3269 |
|
|
2025
Q4 | $79.8K | Buy |
21,573
+90
| +0.4% | +$291 | ﹤0.01% | 3129 |
|
|
2025
Q3 | $56.9K | Buy |
21,483
+17,032
| +383% | +$32.9K | ﹤0.01% | 3234 |
|
|
2025
Q2 | $4.38K | Sell |
4,451
-2,051
| -32% | -$2.05K | ﹤0.01% | 3478 |
|
|
2025
Q1 | $9.36K | Buy |
6,502
+6,013
| +1,230% | +$11.1K | ﹤0.01% | 3250 |
|
|
2024
Q4 | $1.08K | Hold |
489
| – | – | ﹤0.01% | 3518 |
|
|
2024
Q3 | $807 | Buy |
+489
| New | +$987 | ﹤0.01% | 3512 |
|
|
2024
Q2 | – | Sell |
-84,367
| Closed | -$226K | – | 3596 |
|
|
2024
Q1 | $226K | Sell |
84,367
-329
| -0.4% | -$799 | ﹤0.01% | 2411 |
|
|
2023
Q4 | $253K | Sell |
84,696
-1,638
| -2% | -$2.13K | ﹤0.01% | 2385 |
|
|
2023
Q3 | $84.6K | Buy |
86,334
+72,084
| +506% | +$104K | ﹤0.01% | 2656 |
|
|
2023
Q2 | $19.8K | Sell |
14,250
-7,289
| -34% | -$10.2K | ﹤0.01% | 2841 |
|
|
2023
Q1 | $34.2K | Buy |
21,539
+4,287
| +25% | +$22.1K | ﹤0.01% | 2763 |
|
|
2022
Q4 | $107K | Buy |
+17,252
| New | +$123K | ﹤0.01% | 2660 |
|
|
2021
Q4 | – | Sell |
-94,505
| Closed | -$1.14M | – | 3019 |
|
|
2021
Q3 | $1.14M | Buy |
+94,505
| New | +$1.38M | ﹤0.01% | 2134 |
|
|
2021
Q2 | – | Sell |
-31,565
| Closed | -$884K | – | 3238 |
|
|
2021
Q1 | $884K | Sell |
31,565
-12,499
| -28% | -$369K | ﹤0.01% | 2299 |
|
|
2020
Q4 | $1.15M | Sell |
44,064
-33,375
| -43% | -$1,000K | ﹤0.01% | 2058 |
|
|
2020
Q3 | $2.88M | Buy |
77,439
+26,411
| +52% | +$1.05M | 0.01% | 1454 |
|
|
2020
Q2 | $2.61M | Sell |
51,028
-1,559
| -3% | -$65.2K | 0.01% | 1483 |
|
|
2020
Q1 | $1.66M | Buy |
52,587
+1,583
| +3% | +$83.5K | ﹤0.01% | 1563 |
|
|
2019
Q4 | $3.04M | Buy |
51,004
+21,042
| +70% | +$946K | 0.01% | 1494 |
|
|
2019
Q3 | $1.1M | Buy |
29,962
+29,276
| +4,268% | +$1.16M | ﹤0.01% | 1957 |
|
|
2019
Q2 | $32K | Buy |
+686
| New | +$32.2K | ﹤0.01% | 2768 |
|
|
2019
Q1 | – | Sell |
-10,441
| Closed | -$480K | – | 2933 |
|
|
2018
Q4 | $480K | Sell |
10,441
-1,981
| -16% | -$95.4K | ﹤0.01% | 2333 |
|
|
2018
Q3 | $551K | Buy |
12,422
+10,643
| +598% | +$489K | ﹤0.01% | 2352 |
|
|
2018
Q2 | $69K | Hold |
1,779
| – | – | ﹤0.01% | 2776 |
|
|
2018
Q1 | $129K | Sell |
1,779
-665
| -27% | -$48.8K | ﹤0.01% | 2718 |
|
|
2017
Q4 | $165K | Sell |
2,444
-22,628
| -90% | -$1.22M | ﹤0.01% | 2702 |
|
|
2017
Q3 | $1.26M | Buy |
25,072
+1,913
| +8% | +$92.2K | ﹤0.01% | 2022 |
|
|
2017
Q2 | $1.07M | Sell |
23,159
-4,054
| -15% | -$149K | ﹤0.01% | 2077 |
|
|
2017
Q1 | $961K | Buy |
+27,213
| New | +$623K | ﹤0.01% | 2120 |
|
Other funds holding ESPR
GCL
TC
AA
OBAM
Russell Investments Group's ESPR Position: Q2 2026 in Review
Russell Investments Group increased its Esperion Therapeutics (ESPR) stake by 456% in Q2 2026, buying an estimated $274K and bringing the position to 119,340 shares worth $377K. The position accounts for ﹤0.01% of the portfolio, ranked #2912.
Russell Investments Group first reported a position in ESPR in Q1 2017 and has held it in 31 quarters since. The position peaked at $3.04M in Q4 2019. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.
- Russell Investments Group held 119,340 shares of Esperion Therapeutics worth $377K as of Q2 2026.
- Russell Investments Group bought 97,857 Esperion Therapeutics shares in Q2 2026, an estimated $274K.
- Esperion Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2912 holding.
- Russell Investments Group first reported a position in Esperion Therapeutics in Q1 2017 and has held it in 31 quarters since.
- Russell Investments Group's Esperion Therapeutics position peaked at $3.04M in Q4 2019.
- 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.
Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.